Letters to the Editor do not reflect the opinions of The Reporter, its publisher or its staff. You can submit your own Letter to the Editor by email to News@ReadTheReporter.com. Please include your phone number and city of residence. The Reporter will publish one letter per person per week.
Dear Editor:
Continued federal investment in research funding has the opportunity to provide millions of Americans like me with a sense of hope in the fight against Alzheimer’s. Although I was unable to join my fellow Hoosier advocates in Washington, D.C. for the Alzheimer’s Impact Movement (AIM) Advocacy Forum last month, I was proud to support their efforts from home.
Our advocates met with my local congressional office on Capitol Hill, joining over 1,000 other advocates from across the country to paint the Hill purple. One critical issue that they discussed was necessary funding for Alzheimer’s and dementia research – a disease that impacts over seven million Americans annually. As the annual number of new cases of Alzheimer’s and other dementias is projected to double by 2050, now is a crucial time to prioritize research funding.
Alzheimer’s can affect anyone. Thankfully, Congress knows this fight isn’t red or blue – it’s purple. Our bipartisan leaders have played an important role in accelerating the way our nation addresses this disease, but we can’t stop our progress now.
That is why I am asking my Congresswoman Victoria Spartz to support a $113.485 million increase in research funding at the National Institutes of Health (NIH) for FY 2026.
On behalf of the seven million Americans living with this disease and 12 million caregivers, we must continue investing in Alzheimer’s research to bring an end to this devastating disease. The time is now to invest in progress, and invest in hope. Visit alzimpact.org to learn more.
Margaret Churchill
Carmel